RQM+ Appoints Denise Wocko as Head of Global Client Portfolio Management
6.4.2023 18:31:00 EEST | Business Wire | Press release
RQM+, the world’s leading MedTech service provider, today announced the appointment of Denise Wocko as head of global client portfolio management. In her new role, Wocko will work directly with RQM+ clients to provide seamless access to its integrated services, including reimbursement, clinical trials, lab testing and regulatory consulting, that support all phases of the product lifecycle.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230406005546/en/
Denise Wocko, RQM+ Head of Global Client Portfolio Management (Photo: Business Wire)
“We have an incredible opportunity to reduce the risk of clients who have trusted us with managing their regulatory and quality processes for 40 years by helping them navigate each critical step of their product’s journey,” said Wocko. “Our deep expertise in global regulatory consulting – with the largest global team of regulatory experts and former FDA, MHRA and notified body professionals – differentiates us and serves as the foundation for our expanded services. Our clients have asked us to integrate regulatory, clinical, biocompatibility and market access disciplines to give them efficient, end-to-end support. My goal is to make RQM+ the MedTech partner of choice by removing the challenges of a fragmented service landscape that manufacturers are dealing with today.”
Based in Geneva, Wocko has held commercial leadership roles at both niche and large organizations where she worked closely with clients to develop strategic partnerships that meet their objectives. Her experience spans the MedTech, pharmaceutical and biotech industries, as well as with the contract research organizations (CROs) that serve them.
About RQM+
RQM+ is the leading MedTech service provider with the world’s largest global team of regulatory and quality experts. Building upon 40 years of regulatory expertise, we also provide comprehensive clinical trial, lab and reimbursement services – reducing risk throughout the entire product lifecycle for medical devices, digital therapeutics and diagnostics. With more former FDA, MHRA and notified body regulators than any other firm, the RQM+ team has deep expertise in all clinical specialties. We currently works for 19 of the top 20 medical device manufacturers and seven of the top 10 IVD companies. For more information, visit RQMplus.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230406005546/en/
Contact information
Media: Rob Pepper, +1.301.254.6100, rpepper@rqmplus.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Biggest Predictor of Business Growth Is Behavior30.4.2026 10:00:00 EEST | Press release
IDEO, the global design and innovation company, today announced the IDEO Innovation Quotient (IDEO IQ), a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. Those with the highest IDEO IQ scores earned nearly $20 billion in profit last year—50% higher than average and three times more than those ranked at the bottom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429978890/en/ The IDEO Innovation Quotient (IDEO IQ) is a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. The IDEO IQ surveyed 266 leaders in product and innovation roles at 100 of the world’s largest companies across the Media & Technology, Healthcare, and Consumer Goods sectors. The report is the first of its kind to draw a direct line between how companies operate internally and their financial performance. Companies were surve
Suzano Sells 12.7 Million Tonnes of Pulp for the First Time in Its History30.4.2026 01:22:00 EEST | Press release
Suzano(B3: SUZB3 | NYSE: SUZ), the world’s largest pulp producer, announces its results for the first quarter of 2026 (1Q26), achieving a new all‑time record in pulp sales. Over the 12‑month period from April 2025 to March 2026, the company sold 12.7 million tonnes of pulp, the highest volume ever recorded in its history. During the same period, Suzano also sold 1.7 million tonnes of paper across the packaging, printing and writing, specialty, and tissue segments. This unprecedented sales level mainly reflects the increase in production capacity following the start‑up of the Ribas do Rio Pardo pulp mill in the state of Mato Grosso do Sul, as well as Suzano’s strong operational efficiency across its production lines and supply chains, serving customers in more than 100 countries worldwide. In the first quarter of 2026, Suzano sold a total of 3.2 million tonnes, comprising 2.8 million tonnes of pulp and 378 thousand tonnes of paper. Net revenue amounted to BRL 11.0 billion, while adjuste
The Estée Lauder Companies Announces Minority Investment in Luxury Clinical Skin Care Brand 111SKIN29.4.2026 23:30:00 EEST | Press release
The Estée Lauder Companies Inc. (NYSE:EL) today announced a minority investment in 111SKIN, a luxury clinical skin care brand founded by renowned plastic and reconstructive surgeon Dr. Yannis Alexandrides. Terms of the investment were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429495879/en/ 111SKIN's Reparative Collection Founded in 2012, 111SKIN was originally developed by Dr. Alexandrides to accelerate his patients’ healing time following procedures. At the heart of the brand is its innovative NAC Y2™, a pioneering complex designed to support skin repair and maintain a healthy, radiant and resilient complexion. Building on the foundation of this clinical expertise, 111SKIN has developed a portfolio of more than 30 products, anchored by its Black Diamond and Reparative collections and priced from $50 to $1,000. “Skin care is entering a new phase, shaped by the convergence of procedures, longevity and b
IFF Declares Dividend for Second Quarter 202629.4.2026 23:25:00 EEST | Press release
IFF (NYSE: IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.40 per share of its common stock, payable on July 10, 2026 to shareholders of record as of June 18, 2026. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook. © 2026 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved. View source version on businesswire.com: https://www.businesswire.com/news/home/20260429658065/en/
Estithmar Holding Reports 97% Surge YoY in Q1 2026 in Net Profit to QAR 333 Mn29.4.2026 21:25:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced its financial results for the first quarter of 2026, reporting a net profit of QAR 333 million, marking a significant 97% increase compared to the same period last year. The results underscore the strength of the Company’s operating model and the successful execution of its expansion strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429718889/en/ Estithmar Holding Reports 97% Surge YoY in Q1 2026 in Net Profit to QAR 333 Mn (Photo: AETOSWire) The company recorded revenues of QAR 1.455 billion, up from QAR 1.309 billion in Q1 2025. Gross profit rose to QAR 561 million compared to QAR 416 million, representing a year-on-year increase of 35%. EBITDA grew by 73% to reach QAR 473 million, while earnings per share increased by 90% to QAR 0.089. These results reflect comprehensive growth across all key financial indicators, supported by a clear investment vision and the Company’s abili
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
